Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial Cancer

March 21st 2024

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Dr Tanyi on the Use of Pafolacianine for Intraoperative Molecular Imaging in FRα+ Ovarian Cancer

March 21st 2024

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Avutometinib Plus Defactinib Shows High Response Rates in Heavily Treated LGSOC

March 21st 2024

Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.

Advancing Cellular Therapies in Solid Tumors: Current Challenges and Future Directions

March 21st 2024

Jay Spiegel, MD, discusses advancing cellular therapies and challenges in gynecologic cancer treatment.

Preclinical Data Suggest XPO1 Offers Potential Treatment Pathway in TP53 Wild-Type LGSOC and CCOC

March 20th 2024

Treatment with XPO1 inhibitors could be effective and warrants further investigation in low-grade serous and clear cell ovarian cancer.

NXP800 Under Further Investigation in Platinum-Resistant, ARID1A-Mutated Ovarian Cancer

March 19th 2024

A phase 1b trial is investigating the novel GCN2 kinase activator NXP800 in patients with platinum-resistant, ARID1A-mutated ovarian cancer.

DUO-E Trial Data Support Durvalumab Combo as Potential Frontline Option in Advanced Endometrial Cancer

March 19th 2024

Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.

Lenvatinib Plus Pembrolizumab Displays Survival Benefit in Subgroups of Patients With Endometrial Cancer

March 19th 2024

Lenvatinib plus pembrolizumab did not best chemotherapy in pMMR endometrial cancer, but did offer a survival benefit in some subgroups of patients.

Experts Share Top Highlights from the 2024 SGO Annual Meeting on Women’s Cancer

March 19th 2024

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer

March 19th 2024

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer

March 19th 2024

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

AI Models May Serve As Additional Genetic Counseling Resource in Gynecologic Oncology

March 18th 2024

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Disparities in Care Outcomes Persist Between Black and White Patients With Endometrioid Endometrial Carcinoma

March 18th 2024

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

March 17th 2024

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Nab-Sirolimus Elicits Responses in Gynecologic/Peritoneal PEComa

March 17th 2024

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer

March 17th 2024

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell Carcinoma

March 16th 2024

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Tislelizumab Plus Chemo Generates Responses in Locally Advanced Cervical Cancer

March 16th 2024

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Dostarlimab Plus Chemo Demonstrates Survival Advantage in Advanced Endometrial Cancer

March 16th 2024

Dostarlimab plus carboplatin/paclitaxel improved overall survival vs placebo plus chemotherapy in primary advanced or recurrent endometrial cancer.

Pembrolizumab Plus Chemo Generates Favorable OS Trend in Endometrial Cancer

March 16th 2024

The addition of pembrolizumab to chemotherapy led to a favorable overall survival benefit vs chemotherapy plus placebo in endometrial cancer.